Sartorius in the news

RBC maintained a Neutral rating on Sartorius AG stock with a target price of EUR 220.

RBC analyst Charles Weston affirmed a Buy rating for Sartorius Stedim Biotech, setting a target price of EUR 210.

RBC reiterated its 'Sector Perform' rating for Sartorius with a 220 euro price target, adjusting its valuation model for tariffs, acquisitions, and exchange rate changes.

Lonza, Sartorius, and NurExone are actively involved in industrializing exosome production, with Lonza providing contract manufacturing, Sartorius supplying process tools, and NurExone developing both proprietary therapies and commercial exosome offerings.

Sartorius is collaborating with NIBRT to launch a bioprocess training center in Dublin, equipping it with their Pionic platform for over 1,000 trainees annually, while its stock closed at EUR 268.80 on October 6, 2026.

ODDO BHF increased its price target for Sartorius to 335 euros, driven by positive industry sentiment and a potential acquisition in the healthcare sector, leading to a 4.83 percent rise in Sartorius preferred stock.

RBC Capital reiterated its "Outperform" rating for Sartorius Stedim Biotech, adjusting its valuation model to reflect US tariffs, the Mattek acquisition, and currency changes.

An investment in Sartorius vz stock 10 years ago would have yielded a 237.72% return, increasing 10,000 EUR to 33,771.81 EUR.

Sartorius partnered with NIBRT to establish a continuous bioprocessing training center in Dublin and its stock was EUR 251.80.

Sartorius AG reported strong financial performance in 2025 and 2026, with consistent growth, improved margins, and robust consumables demand, driven by strategic investments and innovation.

Oddo BHF increased its price target for Sartorius Stedim Biotech stock to EUR 281, following strong first-half 2026 results and a focus on bioprocessing demand recovery.

Sartorius Stedim Biotech's stock received upgraded analyst price targets following its first-half 2026 financial results, which showed revenue of EUR 1.527 billion and a strong EBITDA margin.

Sartorius Stedim Biotech's stock received increased analyst price targets due to strong first-half 2026 results and positive management guidance, despite high valuation expectations and the stock trading below its yearly high.

Berenberg increased its target for Sartorius stock to EUR 280.00 despite the company missing Q2 2026 revenue and EPS estimates, setting the stage for a critical October 22, 2026 earnings report.

Goldman Sachs raised its price target for Sartorius stock to EUR 244, expecting Q3 earnings above consensus due to bioprocessing recovery, while maintaining a Neutral rating.

Sartorius Vz stock declined in ranking within a technology stock investment universe managed by an AI-driven advisor.

Sartorius announced a partnership with NIBRT to create a bioprocessing training center in Dublin, while its stock traded at EUR 251.80.

Sartorius Stedim celebrated its Tunisian manufacturing site's 25th anniversary, highlighting significant investments and expansion, while its stock remained stable and an audit tender was announced.

Sartorius stock is attracting new analyst targets from Barclays, Goldman Sachs, and JPMorgan ahead of its Q3 earnings report on October 22, with varying outlooks on its recovery and valuation.

ODDO BHF raised its price target for Sartorius preferred shares from 285 to 335 euros, maintaining an "Outperform" rating.